Why Adc Therapeutics SA (NYSE:ADCT) Stock Slipped -12.07% in Last Month?
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
initiated: Cantor Fitzgerald Recommends Adc Therapeutics SA (NYSE:ADCT) Stock to “an Overweight”
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
The growth of Adc Therapeutics SA (ADCT) Stock is expected to continue
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
Is it possible to sustain this rally? Adc Therapeutics SA (ADCT) Stock
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
The performance of Adc Therapeutics SA (ADCT) Stock has improved
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
What makes Adc Therapeutics SA (ADCT) Stock unique?
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
There Is Nothing Like Adc Therapeutics SA (ADCT) Stock
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
The latest Adc Therapeutics SA (ADCT) Stock Technical Bulletin
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
